Journavx is the first and only approved non-opioid oral painkiller and the first new class of pain medicine approved in more ...

Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday’s market open after the Food and Drug Administration approved ...

Biotech stocks remain a hot sector for retail traders on Stocktwits, which collectively boast over 3.45 million followers. In ...

Shares of Teva Pharmaceutical Industries ( TEVA -13.66%) were slipping Wednesday. The company's stock lost 13.5% as of 1:15 p ...

Cardinal Health had $210 billion in pharmaceutical and specialty drugs sales in fiscal 2024, up 11% year-over-year, helped in large part by GLP-1 sales. In Q4, segment sales rose 13% to $55 billion, ...

With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX stock over the recent years has been far from consistent, and has largely ...

February is observed as American Heart Month, a period dedicated to raising awareness about heart health. The first American Heart ...

Vertex Pharmaceuticals (VRTX – Research Report) received a Buy rating and a $480.00 price target from Cantor Fitzgerald analyst Olivia Brayer ...

Discover the top-performing biotech stocks in 2024! From oncology to psychedelics some companies showed remarkable results.

The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...

Driven by rapid innovations and the integration of modern technologies, the biotech sector is experiencing robust growth.

The pharma industry is expected to grow 4.7% annually, reaching $1.4 trillion by 2029. [Sign up for stock news with our Invested newsletter.] Not only are pharmaceutical stocks excellent defensive ...